Isatuximab Shows Efficacy, Acceptable Safety Across Multiple Myeloma Trials
At a median time to response of 1 month, isatuximab elicited a median duration of response of 10.3 months in patients with multiple myeloma.
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists
Rhenium Obisbemeda Improves Survival in Recurrent Glioblastoma
Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.
PFS Improves in BRAF V600E+ CRC With Encorafenib Combo
Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.
Teclistamab Shows Sustained Efficacy in R/R Multiple Myeloma
Combination therapies with teclistamab exhibited a superior overall response rate vs teclistamab monotherapy in relapsed/refractory multiple myeloma.
Ivonescimab Combo Shows Meaningful PFS Improvement in EGFR-Mutant NSCLC
Ivonescimab plus chemotherapy reduced the risk of disease progression or death by 48% vs chemotherapy alone in patients with EGFR-mutant NSCLC.
Pivotal Presentations That May Shape the Breast Cancer Standard of Care
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC
Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.
Developers Withdraw BLA for HER3-DXd in Advanced EGFR-Mutant NSCLC
After a lack of significant topline overall survival data from the phase 3 HERTHENA-Lung02 trial, the application for HER3-DXd in NSCLC was withdrawn.
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US
FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC
The decision is based on results from the phase 1/2 SOHO-01 trial evaluating the agent in patients with advanced HER2-mutant non–small cell lung cancer.
Anti-GPRC5D CAR T Cells May Be Viable Multiple Myeloma Salvage Therapy
A Chinese phase 2 trial found that anti-GPRC5D CAR T-cell therapy elicited an ORR of 84% in patients with relapsed or refractory multiple myeloma.
Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer
Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.
FOLFIRINOX Improves PFS in Locally Advanced Pancreatic Cancer
Phase 3 data may support FOLFIRINOX as a standard of care in fit patients with locally advanced pancreatic cancer.
Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma
Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.
QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer
A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
ASCO 2025: Key Anticipated Updates Across Cancer Care
Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.
High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC
Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.
EBC-129 Receives FDA Fast-Track Designation for PDAC
Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
Scalp-cooling may enhance patients’ quality of life when managing hair loss associated with cancer treatment.
PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC
Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.
Managing Dermatologic Complications in Oncology
Diverse dermatologic AEs, such as hair and nail toxicities, can be associated with various cancer treatments.
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Sacituzumab Govitecan Improves PFS in 1L PD-1/PD-L1 Inhibitor Ineligible mTNBC
In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.
Avutometinib/Defactinib Combo May Elicit Efficacy in Metastatic PDAC
Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.
IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer
Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.
Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer
Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study